Richard R. Furman, MD

Articles

Dr. Furman on Current Treatment Options in CLL

May 10th 2022

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Q&A: Early Treatment of CLL

January 5th 2022

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Q&A: Modifying and Switching Therapies in CLL

January 5th 2022

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Novel Treatments for the Management of CLL

January 5th 2022

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Choosing the Appropriate Treatment Strategy in CLL

December 22nd 2021

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Using Noncovalent BTK Inhibitors for the Management of CLL

December 22nd 2021

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Resistance Mechanisms to BTKi in CLL

December 15th 2021

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Role of Fixed-Dose Regimens in CLL

December 15th 2021

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

ELEVATE-RR and ALPINE Trials in Relapsed CLL

December 8th 2021

Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.

BTK Inhibitors in the Management of CLL

December 8th 2021

Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.

Dr. Furman on FDA-Approved BTK Inhibitors in B-Cell Malignancies

June 23rd 2020

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Dr. Furman on the Safety of Acalabrutinib in Hematologic Malignancies

June 16th 2020

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

Dr. Furman on Differences Between BTK Inhibitors in B-Cell Malignancies

June 10th 2020

Richard R. Furman, MD, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

Dr. Furman on Acalabrutinib Monotherapy in CLL

February 11th 2020

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Furman on Frontline Treatment Selection in CLL

November 22nd 2019

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

CLL in the Era of Targeted Therapies

December 12th 2017

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Dr. Furman on Exciting Available Agents for Patients With CLL

September 1st 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

Dr. Furman on Considering Factors for Upfront Therapy in CLL

August 15th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).

Dr. Furman on Second-Generation BTK Inhibitors in CLL

August 3rd 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).